Our Journey

An innovative company founded and managed by a highly-experienced team ...

... developed a novel technology based on a nanobody with low toxicity and high efficacy called Pepcrotament...

... which turns into a  breakthrough platform to treat malignancies including, but not limited to, Triple Negative Breast Cancer

PHP Biotech was created to discover and develop an innovative approach to deal with solid cancers including, but probably not limited to, breast, lung, colorectal and pancreatic cancers, which are among the most diagnosed cancers worldwide. Current treatments have made progress against theses cancers, but not enough. With these unmet needs in mind, PHP Biotech research team has developed a pioneering compound (3-NAnTc) that is monten with a humanized single-domain antibody (sdAb) to enhance delivery and effectiveness in the fight against the most prevalent malignancies. Our technology allows multiple configurations of the sdAB, broadening the range of therapeutic possibilities and creating a platform of products to treat aggressive malignancies such as TNBC. The molecule PHP Biotech developed has shown an ability to promote apoptosis while harnessing the development of metastatic disease allied with evidence of minimal toxicity. We envision Pepcrotament being used as a monotherapy or as an add-on therapy against aggressive disease. Its favorable therapeutic ratio allows us to also consider its use in the maintenance setting so that patients can continue with their productive life while fighting their disease.

Eduardo Braun, MD

Medical Oncologist

Chicago. IL

A Highly Experienced
Management Team

Advisory Board

Humberto Matsuda

Shareholder /
Board Member

+25 Years of
experience

Priscila Spadinger

Shareholder/ Board Member

Renata
Vilela

Shareholder /
Board Member

Maria R. Torqueti, PhD

Shareholder /
Board Member

+25 Years of
experience

Leonardo de S. Teixeira

Shareholder /
Board Member

+25 Years of
experience

Paulo
Nigro

Shareholder / Board Member
+25 Years of
experience

Executive comitee

Moacyr Bighetti

Executive
Board Member

+20 Years of
experience

Oswaldo Bighetti Neto

Executive Board Member
+25 Years of
experience

Eduardo Braun, MD

Oncologist, Executive Board Member

Kleber Miranda

Executive Board Member

+25 Years of
experience

Jorge Brasil, MD

Executive Board Member

+20 Years of
experience

PHP Biotech Internacional Inc. Texas, US

Robert Gahagen

CEO

+30 Years of
experience

Eduardo
Motti

COO

+30 Years of
experience

João Marcelo Carucci

CFO

Patricia Bezerra, PhD

Research
Leader

PHP Biotech

Focuses on product development, and the time has come to move on...

...with partners...

...to accelerate the
HOPE FOR LIFE

Our focus

High Unmet Needs in Solid Tumors

The Global Cancer Observatory, 2020 / Delivering innovation: 2020 oncology market outlook. McKinsey & Company / Data Bridge Market Research Market Analysys Study 2022

TNBC: a Tumor with High Unmet Needs
Facts & Figures

Delivering innovation: 2020 oncology market outlook. McKinsey & Company / Data Bridge Market Research Market Analysys Study 2022/  https://dailynews.ascopubs.org/do/considering-high-unmet-need-triple-negative-breast-cancer, acessed in December 11th, 2022 / https://www.breastcancer.org/types/triple-negative, accessed on December 11th, 2022/ https://www.cancer.org/cancer/breast-cancer/about/types-of-breast-cancer/triple-negative.html, accessed on December 11th, 2022 / https://www.uptodate.com/contents/er-pr-negative-her2-negative-triple-negative-breast-cancer, accessed on December 11th, 2022

Our Breakthrough Technology

Harnessing Brazilian Biodiversity

Enhanced Efficacy-Safety Profile With Pepcrotament

A Novel Mechanism of Action

Pipeline

A Unique Opportunity

A High-Potential Treatment Platform

Scientifc Paper

PHP Contact Information